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and thyroid stimulating hormone receptor (TSH-R) and for 
some miRNAs involved in thyroid neoplasia and targeting 
THRβ. The mRNA levels of each tumor tissue were com-
pared with their correspondent normal counterpart.
Results THRβ transcript was down-regulated in all 
PTCs examined. No significant differences were found 
between intermediate- vs low-risk PTCs patients, and 
BRAF-mutated vs BRAF wild-type groups. THRβ expres-
sion was directly correlated with NIS, TPO, Tg and TSH-R, 
and inversely correlated to miR-21, -146a, -181a and -221 
expression.
Conclusions Our results demonstrate that down-regu-
lation of THRβ is a common feature of PTCs. While it is 
not associated with a more aggressive phenotype of PTC, it 
correlates with the reduction of all the markers of differen-
tiation and is associated with overexpression of some miR-
NAs supposed to play a role in thyroid tumorigenesis.
Keywords Thyroid hormone receptor · Papillary thyroid 
carcinoma · miRNA · BRAF
Introduction
Thyroid hormone receptors (THRs) mediate the biological 
activities of the thyroid hormones in development, growth, 
differentiation and metabolism [1, 2]. Detection of alterations 
in the expression levels and/or integrity of THR genes in many 
neoplasms has made the analysis of these genes in human 
cancers an area of considerable interest. Several alterations 
have been described, including hypermethylation in breast 
cancer [3, 4], altered splicing in hepatocellular cancer [5] and 
loss of heterozygosity/deletions in breast, lung and melanoma 
cancer [2, 6–8], all resulting in reduced/lost expression of 
THR in tumor cells. Moreover, Martinez-Iglesias et al. have 
Abstract 
Purpose Down-regulation of thyroid hormone receptor 
beta (THRβ) gene has been described in several human 
malignancies, including thyroid cancer. In this study, 
we analyzed THRβ mRNA expression in surgical speci-
mens from a series of human papillary thyroid carcinomas 
(PTCs), characterized by their genotypic and clinical–bio-
logical features.
Methods Thirty-six PTCs were divided into two groups 
according to the 2009 American Thyroid Association risk 
classification (17 low, 19 intermediate), and each group 
was divided into subgroups based on the presence or 
absence of the BRAFV600E mutation (21 BRAF mutated, 
15 BRAF wild type). Gene expression was analyzed using 
fluidic cards containing probes and primers specific for 
the THRβ gene, as well as for genes of thyroperoxidase 
(TPO), sodium/iodide symporter (NIS), thyroglobulin (Tg) 
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shown that THRβ1 re-expression in hepatocarcinoma and 
breast cancer cells was able to reduce tumor growth, enhanc-
ing expression of epithelial markers and diminishing that of 
the mesenchymal marker vimentin [9]. Gene mutations, small 
deletions and variations in the THR RNA and protein levels 
[10] have also been reported in thyroid cancers, in which a 
role of THRβ1 as potential suppressor of thyroid tumorigen-
esis has been proposed [11].
In the last years, miRNA expression profiling of human 
tumors has permitted to identify signatures associated with 
the diagnosis, staging, prognosis and response to treat-
ment [12] and several studies have demonstrated that up-
regulation of oncogenic miRNAs or down-regulation of 
miRNAs functioning as tumor suppressors is associated 
with carcinogenesis [13, 14]. Many groups have analyzed 
the expression of miRNAs in thyroid neoplasia and have 
shown an altered regulation of several miRNAs, proposing 
a role for some of them in papillary thyroid cancer (PTC) 
tumorigenesis [reviewed in 15, 16]. Noteworthy, a subset 
of miRNAs that are up-regulated in PTC tumors (miR-21, 
miR-146a, miR-181a and miR-221) has been described to 
target and to inhibit the expression of THRβ [17].
In this work, we have examined 36 PTCs, well charac-
terized in their clinical–biological properties and genotypic 
alterations, to study THRβ expression and its correlation 
with the degree of aggressiveness, the presence of BRAF 
oncogene activating mutation and the expression of mark-
ers of thyrocyte differentiation thyroperoxidase (TPO), 
sodium/iodide symporter (NIS), thyroglobulin (Tg) and 
thyroid stimulating hormone receptor (TSH-R). Moreover, 
in the same tumors, we analyzed the expression levels of 
miRNAs targeting THRβ.
Materials and methods
Patients and tissues
Thirty-six patients with sporadic PTCs have been enrolled at 
the University Hospital of Rome, Sapienza. For each patient, 
a sample of thyroid tumor tissue and contralateral non-tumor 
(normal) tissue were collected immediately after thyroidec-
tomy, snap-frozen and stored in liquid nitrogen. All samples 
were reviewed by a single pathologist, who confirmed the 
diagnosis of PTC, identified the histological variant of the 
tumor and evaluated the percentage of tumor cells (all tumor 
tissues selected had a percentage of tumor cells higher than 
60 %). Clinical data were collected by retrospective review 
of hospital charts, and tumors were staged according to the 
criteria of the AJCC/UICC TNM classification, 7th edition 
[18]. The 36 cases were risk-stratified on the basis of clinical 
and histological data in accordance with the 2009 American 
Thyroid Association (ATA) risk of recurrence staging system 
[19]. The study was approved by the local medical ethics 
committee and written informed consent was obtained from 
all patients whose tissues were analyzed.
Mutational analysis of BRAF
The mutational status of BRAF was analyzed by direct 
sequencing in cDNA samples of tumor tissues. The exon 
15 of BRAF was amplified by PCR (Table S1) and the 
products sequenced with the BigDye Terminator version 
3.1 Cycle Sequencing kit in an automated 3130xl analyzer 
(Life Technologies, Foster City, CA, USA). All PCR and 
sequencing reactions were repeated at least twice to con-
firm the presence of the mutation V600E.
RNA isolation from thyroid tissues and reverse 
transcription
Total RNA was extracted from tissue samples using Trizol 
reagent (Life Technologies) [20] according to the manufac-
turer’s instructions. RNA concentration was measured by a 
NanoDrop Spectrophotometer (Thermo Fisher Scientific, 
Inc., Waltham, MA, USA). First-strand cDNA synthesis 
was performed following the protocol provided with the 
High Capacity cDNA Reverse Transcription kit (Life Tech-
nologies), as previously described [21].
Gene expression analysis
In the screening step, mRNA levels of THRβ, NIS, TPO, 
Tg and TSH-R genes were assessed in thyroid tissues by 
real-time PCR using custom Taqman Low Density Arrays 
(TLDA, Life Technologies). Each TLDA was configured 
with specific predesigned assays (TaqMan Gene Expression 
Assays, Life Technologies) and four housekeeping genes 
(Glyceraldehyde-3-Phosphate Dehydrogenase; Beta-actin; 
Hypoxanthine Phosphoribosyltransferase 1 and Beta-2 
microglobulin) were included to normalize RNA expres-
sion levels. The TaqMan arrays were set up as previously 
described [22] and all the PCR reactions were performed 
on a 7900 HT Fast Real-time PCR System (Life Technolo-
gies). Ct values were calculated with SDS 2.4 software 
(Life Technologies) and data analysis was carried out using 
RQ Manager 1.2.1 software (Life Technologies). Beta-
actin was chosen as endogenous control because of its least 
variance among samples. Final results were determined by 
the comparative 2−ΔΔCt method and expressed as relative 
expression normalized to a calibrator sample.
miRNA expression analysis
TaqMan® Array Human MicroRNA Card Set v3.0 (Life 
Technologies) was used to evaluate the expression levels 
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of miR-21, miR-146a, miR-181a and miR-221. Total RNA 
(500 ng) was reverse transcribed using high-capacity cDNA 
reverse transcription kit (Life Technologies) and Mega-
plexTM RT primer pool (Life Technologies). Real-time 
PCR was performed on a 7900 HT Fast Real-Time PCR 
System (Life Technologies). Ct values were calculated with 
SDS 2.4 software (Life Technologies) and data analysis 
was carried out using Expression Suite v1.0.3 (Life Tech-
nologies). U6 was chosen as endogenous control due to its 
least variance among samples. The relative level of miRNA 
expression was calculated by the comparative 2−ΔΔCt 
method using Expression Suite v1.0.3 (Life Technologies).
Statistical analysis
Statistical analysis was carried out using GraphPad Prism 
version 5.0 statistical software (GraphPad Software Inc., 
San Diego, CA, USA). Real-time PCR results are expressed 
as mean ± standard deviation (SD). Mann–Whitney test 
and Student’s t test were used to evaluate intergroup dif-
ferences. Correlations between quantitative variables were 
analyzed by the Spearman rho rank correlation coefficient. 
p values lower than 0.05 were considered statistically 
significant.
Results
Clinical and pathological features
We examined 36 tissues from patients with apparently 
sporadic PTC. They included 17 cases with a low risk of 
recurrence, and 19 with an intermediate risk based on the 
2009 ATA risk stratification system. Table 1 summarizes 
the characteristics of study population at the time of the 
primary treatment, which consisted in total or near total 
thyroidectomy, with or without radioactive iodine remnant 
ablation. Among the low-risk patients and those at interme-
diate risk, 7 (41.1 %) and 14 (73.7 %), respectively, carry 
the BRAF V600E mutation (Fig. 1).
Expression of THRβ and correlation 
with thyroid‑specific genes in PTCs
Analysis of mRNA showed that expression levels of 
THRβ were lower in tumor tissues than in the normal 
counterpart tissues (Normal tissues = 1 ± 0.536, Tumor 
tissues = 0.618 ± 0.434, p = 0.0021) (Fig. 2). By com-
parison of the subgroups, no significant deregulation was 
found between low-risk PTCs and intermediate-risk PTCs 
(Fig. 2), as well as between BRAF V600E PTCs and BRAF 
wild-type PTCs (Fig. 2). The expression of THRβ was then 
compared to mRNA levels of the thyroid-specific genes 
NIS, TPO, Tg and TSH-R. A statistically significant and 
direct correlation with THRβ levels was detected for all of 
the thyrocyte-specific genes examined (Table 2). In addi-
tion, as reported in Fig. 3, NIS mRNA levels showed the 
major significant reduction and TSH-R the minor. Moreo-
ver, expression levels of TPO were significantly lower in 
PTC with intermediate risk and in BRAF V600E PTCs 
(Table S2). No significant deregulation was found for NIS, 
Tg and TSH-R (Table S2).
Expression of miRNAs in PTC tissues
Twenty-one PTC tissues of the present cohort were also 
analyzed for the expression level of a subset of miRNA 
previously predicted to target THRβ (miR-21, miR-146a, 
miR-181a and miR-221) [22]. Expression levels of miR-
21, miR-181a and miR-221 resulted significantly higher 
in tumor tissues compared to normal tissues (Table S3). 
According to ATA risk and BRAF mutational status, no sig-
nificant deregulation was found (Table S3).
As reported in Fig. 4, a higher expression of miR-21, 
miR-146a, miR-181a and miR-221 was observed in almost 
all those tumor tissues displaying lower levels of THRβ. 
However, Spearman correlation of miRNA and THRβ data 
did not show a statistically significant association (data not 
shown). miRNA expression levels were then compared 
with those of thyroid-specific genes NIS, TPO, Tg and 
TSH-R. As shown in Fig. S1, a statistically significant and 
inverse correlation was found between expression levels of 
TG and both miR-21 and miR-146a, and between TPO and 
miR-21.
Discussion
In the last two decades, the incidence of thyroid cancer, 
the most common malignancy in the endocrine system, has 
greatly increased [23] and about 80 % of all cases are rep-
resented by PTCs. Although most of these tumors present 
a good prognosis (survival rates of 90–95 % at 5 years), 
there is a minority of patients unresponsive to treatment 
based on association of surgery and radioactive iodine. The 
loss of differentiation of the transformed cells, and in par-
ticular the reduction/loss of expression of functioning NIS 
protein represents a major cause of lack of responsiveness 
to radioiodine treatment in case of recurrent/metastatic dis-
ease [24–27]. Several genetic and epigenetic alterations 
are involved in the loss of differentiation of PTCs and the 
acquisition of more aggressive phenotype [28–31]. Thus, 
elucidating the molecular mechanisms that contribute to 
dedifferentiation and aggressiveness of PTCs may help to 
tailor diagnostic and therapeutic strategies and to propose 
novel targeted therapy approaches.
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Recent investigations showed that alterations causing a 
marked impairment of the THR expression and function can 
influence the process of thyroid tumorigenesis [10, 32]. By 
analyzing the expression of THRβ in 17 PTCs, Kim et al. 
observed a significant reduction of its mRNA expression 
levels in cancer tissues [10]. A functional role of THRβ was 
further supported by in vitro data in which reactivation of 
the silenced THRβ expression delayed thyroid tumor pro-
gression [10]. Moreover, Zhu et al. have demonstrated in 
a mouse model of metastatic follicular thyroid cancer that 
functional loss of THRβ and THRα gene promoted the 
development of thyroid carcinomas and metastasis, suggest-
ing that THRs could function as a tumor suppressor in this 
experimental model [11]. In our study, analysis of THRβ 
Table 1  Characteristics of the study population at the time of primary treatment
All patients had no clinical evidence of distant metastases at the time of primary treatment
F female, M male, PTC-cl classical variant, PTC-fv follicular variant, T tumor, N node, ATA American Thyroid Association, wt wild type
a The 2009 American Thyroid Association risk stratification staging system
No. Sex Age Histological 
variant
T N Tumor  
size (mm)
Tumor foci Extrathyroid 
extension
ATA riska BRAF mutational 
status
1 M 58 PTC-fv T1b N0 18 Unifocal None Low V600_K601delinsE
2 M 60 PTC-cl T1b N0 12 Unifocal None Low V600E
3 F 61 PTC-cl T2 N0 25 Unifocal None Low V600E
4 F 66 PTC-cl T1a Nx 6 Multifocal None Low V600E
5 M 27 PTC-cl T1 N0 11 Multifocal None Low V600E
6 F 23 PTC-cl T1b Nx 14 Multifocal None Low V600E
7 M 45 PTC-cl T1b N0 18 Unifocal None Low V600E
8 F 50 PTC-cl T1b N0 12 Multifocal None Low wt
9 F 40 PTC-fv T1a Nx 4 Unifocal None Low wt
10 F 35 PTC-cl T1 N0 9 Multifocal None Low wt
11 F 34 PTC-fv T1b Nx 20 Unifocal None Low wt
12 M 51 PTC-fv T1a Nx 6 Unifocal None Low wt
13 F 37 PTC-cl T1b Nx 20 Unifocal None Low wt
14 F 33 PTC-cl T1b Nx 14 Unifocal None Low wt
15 M 31 PTC-cl T1b Nx 11 Unifocal None Low wt
16 M 58 PTC-cl T1a Nx 5 Unifocal None Low wt
17 F 60 PTC-cl T1a Nx 5 Unifocal None Low wt
18 F 64 PTC-cl T3 N0 15 Unifocal Minor Intermediate V600E
19 F 46 PTC-cl T3 N1 30 Unifocal Minor Intermediate V600E
20 F 46 PTC-cl T3 N0 15 Unifocal Minor Intermediate V600E
21 F 33 PTC-cl T1b N1a 11 Multifocal None Intermediate V600E
22 F 42 PTC-cl T1b N1 15 Multifocal None Intermediate V600E
23 F 34 PTC-cl T1 N1 13 Unifocal None Intermediate V600E
24 F 52 PTC-cl T3 N0 8 Multifocal Minor Intermediate V600E
25 F 62 PTC-cl T3 N0 16 Unifocal Minor Intermediate V600E
26 M 37 PTC-cl T3 Nx 12 Unifocal Minor Intermediate V600E
27 M 35 PTC-cl T1b N1b 20 Multifocal None Intermediate V600E
28 M 42 PTC-cl T3 N1b 14 Multifocal Minor Intermediate V600E
29 F 65 PTC-cl T3 N0 9 Unifocal Minor Intermediate V600E
30 F 46 PTC-cl T3 N0 12 Unifocal Minor Intermediate V600E
31 F 50 PTC-cl T3 N1 10 Unifocal Minor Intermediate V600E
32 F 41 PTC-fv T3 N1a 15 Unifocal Minor Intermediate wt
33 F 19 PTC-cl T1b N1b 20 Unifocal None Intermediate wt
34 F 34 PTC-cl T3 N0 12 Unifocal Minor Intermediate wt
35 M 27 PTC-cl T3 N1 25 Multifocal Minor Intermediate wt
36 F 42 PTC-cl T3 N1 9 Unifocal Minor Intermediate wt
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expression was performed in a wider cohort of PTCs. In 
all 36 tumors examined, the transcript was down-regulated 
compared with the corresponding normal tissue. However, 
such as NIS, Tg and TSH-R, we did not find significant dif-
ferences of THRβ mRNA levels by comparing the groups 
in terms of tumor extent and risk of having structural per-
sistent/recurrent disease based on the 2009 ATA risk strati-
fication staging system [19]. Thus, the reduced expression 
of THRβ may not be considered as a marker of aggressive-
ness, at least in this cohort of PTCs. This finding is also 
strengthened by the absence of significant differences in 
THRβ expression levels between the subgroups of tumors 
presenting the BRAF V600E mutation or not. BRAF V600E 
is the most common genetic alteration found in PTCs [33] 
and is associated with a reduced expression of the genes 
involved in iodide metabolism [34], the presence of worri-
some clinicopathologic features, and a significantly higher 
risk of recurrence than BRAF wild-type tumors [30, 35].
Fig. 1  Classification of human 
PTCs. Tumors were assigned to 
groups according to the 2009 
ATA risk of recurrence staging 
system (intermediate and low 
risk) and the presence of BRAF 
V600E mutation
36
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Fig. 2  Expression of THRβ in human PTCs. Expression levels of 
THRβ in tumor tissues are lower than corresponding normal. No sig-
nificant differences were found between the PTCs at ATA intermedi-
ate risk vs low risk of recurrence, and BRAF V600E vs BRAF wild-
type PTCs. Data represent the mean ± standard deviation. p value 
was obtained by Mann–Whitney test. **0.001 < p < 0.01. ns not sig-
nificant
Table 2  Correlation between THRβ expression and thyroid-specific 
genes (NIS, TPO, Tg and TSH-R)
a Spearman rho rank correlation coefficient
Gene ra p value
NIS 0.3771 0.0098
TPO 0.3917 0.0037
Tg 0.4504 0.0007
TSH-R 0.5049 0.0001
1.5
1.0
0.5
0
NIS TPO Tg TSH-R
- - - - - - - - - - - - - - - - - - - - - - - - - - - -
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Fig. 3  Expression of thyroid-specific genes in human PTCs. Expres-
sion levels of NIS, TPO, Tg and TSH-R in tumor tissues are lower 
than corresponding normal, set equal to one. Data represent the 
mean ± standard deviation. p values were obtained by Mann-Whit-
ney test. *0.01 < p < 0.05; ***p < 0.001
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In this series of PTCs, analysis of expression levels 
of thyroid-specific genes, which confirmed our previ-
ous finding regarding the presence of the lowest lev-
els of NIS and the close to normal levels of TSH-R [21], 
revealed that THRβ expression was directly correlated 
with all the genes examined, suggesting for the loss of 
THR intra-thyroidal expression the behavior as a marker 
of differentiation.
It is now well established that disregulation of the profile 
of miRNAs expression occurs in a variety of malignancies, 
where they are emerging as oncogenes or tumor suppressor 
genes [12–14]. There are many reports about the expression 
of miRNAs in thyroid tumors [reviewed in 15, 16]. Interest-
ingly, up-regulation of miR-21, miR-181a, miR-146a, and 
miR-221 has been described as an important mechanism of 
silencing of THRβ [17]. In our study, we found the upregu-
lation of miR-21, miR-181a, miR-146a and miR-221 in 
all tumor tissues displaying low levels of THRβ. Although 
the correlation did not reach a statistical significance, the 
general trend confirms the results of Jazdzewski [17], sug-
gesting that an up-regulation of these miRNAs might be 
responsible for the down-regulation of THRβ in PTCs. As 
for other thyroid-specific genes, a statistically significant 
and inverse correlation was found between expression lev-
els of Tg and both miR-21 and miR-146a, and also between 
TPO and miR-21.
In conclusion, our findings demonstrate that a reduction 
of THRβ gene expression is a common feature of PTCs 
even if not associated with a more aggressive phenotype 
of the tumors. Moreover, it is directly correlated with the 
reduction of all the markers of differentiation and associated 
with overexpression of some miRNAs supposed to play a 
role in thyroid tumorigenesis. Overall, our results suggest 
that THRβ could represent an additional thyroid differentia-
tion marker.
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